Shares of pharmaceutical giant Merck & Co. advanced on Friday, closing at $121.41 after a notable 1.8% gain. The move was catalyzed by a positive analyst action from Deutsche Bank, which upgraded the stock and established a new price target of $150. During the trading session, the stock reached a new 52-week peak of $123.33 before U.S. equity markets closed ahead of the Presidents Day holiday.
Navigating the Patent Cliff
The upgrade from Deutsche Bank analyst James Shin centers on a contrarian view of Merck's future. Shin argues that the market is currently undervaluing the company due to excessive pessimism surrounding the impending "patent cliff"—the period when exclusivity expires for key drugs, most notably the blockbuster cancer immunotherapy Keytruda later this decade. Shin sees a "clear path" for Merck to manage this transition, drawing parallels to AbbVie's strategy following the loss of exclusivity for its own top-selling drug, Humira.
This outlook comes as Merck's management has recently highlighted a perceived disconnect with Wall Street. Earlier in February, the company provided 2026 revenue guidance in the range of $65.5 billion to $67.0 billion. CEO Rob Davis pointed to differing interpretations of how the market is accounting for the impact of older drugs losing patent protection.
Pipeline in Focus at Upcoming Conference
Investor attention is now turning to Merck's near-term pipeline catalysts. The company announced plans to present new clinical data for its oncology portfolio at the ASCO Genitourinary Cancers Symposium, scheduled for February 26-28. Key presentations will include late-breaking results from the KEYNOTE-B15 study, evaluating a combination of Keytruda and Padcev for bladder and kidney cancers. Dr. Marjorie Green, a senior Merck executive, expressed enthusiasm about sharing these new findings from both established and emerging programs.
Friday's rally occurred within a mixed broader market context. The S&P 500 eked out a modest gain, while the Nasdaq Composite dipped slightly, as investors exhibited some risk aversion heading into the three-day weekend, despite a softer-than-expected inflation reading.
Insider Trading and Market Mechanics
Separately, regulatory filings revealed insider selling activity. Merck's Chief Marketing Officer, Chirfi Guindo, sold 10,000 shares on February 12 at a weighted average price of approximately $121.46 per share. This transaction followed an amended filing indicating plans to sell up to 20,000 shares, with Morgan Stanley acting as the broker.
With U.S. markets closed on Monday for the federal holiday, trading will not resume until Tuesday. This holiday-thinned liquidity could lead to a choppy opening session. Traders will be watching to see if Friday's momentum persists and whether news flow from the upcoming medical conference sustains focus on Merck's oncology pipeline.
The next major scheduled event for the company is the release of its first-quarter financial results on April 30. This report will serve as a critical checkpoint, with investors scrutinizing it for any updates to the full-year 2026 guidance and, more importantly, for further clarity on management's strategic roadmap for the post-Keytruda era. The central question remains whether the company can successfully execute its plan to offset the eventual revenue decline from its flagship product with new innovations from its research pipeline.
